The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

ARIAD Announces Presentations of Preclinical Data at American Association for Cancer Research Annual Meeting

Monday, March 26, 2012

ARIAD Announces Presentations of Preclinical Data at American Association for Cancer Research Annual Meeting07:35 EDT Monday, March 26, 2012 CAMBRIDGE, Mass. (Business Wire) -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its schedule of preclinical data presentations to be made at the American Association for Cancer Research (AACR) Annual Meeting 2012, taking place Saturday, March 31 through Wednesday, April 4, 2012, in Chicago. Listed below are the details of presentations at AACR that describe ARIAD's product candidates or research programs. There will be three presentations of data on ARIAD's investigational targeted therapies, ponatinib and AP26113; and one presentation of work on choline kinase, a discovery program which is not being pursued further at this time. Each presentation is currently available in abstract form: Title: Ponatinib, a potent pan-BCR-ABL inhibitor, retains activity against gatekeeper mutants of FLT3, RET, KIT, PDGFRα/β and FGFR1 Date & Time: Sunday, April 1, 1:00–5:00 p.m. (Poster) Abstract: #853 Location: Hall F, Poster Section 32   Title: AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC Date & Time: Monday, April 2, 8:00 a.m.–12:00 p.m. (Poster) Abstract: #1794 Location: Hall F, Poster Section 29   Title: Fibroblast growth factors in head and neck cancer: Genetic alterations and therapeutic targeting with ponatinib Date & Time: Monday, April 2, 1:00–5:00 p.m. (Poster) Abstract: #2832 Location: Hall F, Poster Section 32   Title: Small molecule inhibitors of choline kinase lead to reduced phosphocholine levels and induction of apoptosis in cancer cells Date & Time: Tuesday, April 3, 8:00 a.m.–12:00 p.m. (Poster) Abstract: #3236 Location: Hall F, Poster Section 9   About ARIAD ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD's approach to structure-based drug design has led to three internally discovered, molecularly targeted product candidates for drug-resistant or difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas and non-small cell lung cancer. For additional information, visit http://www.ariad.com or follow us on Twitter. ARIAD Pharmaceuticals, Inc.For Investors:Maria E. Cantor, 617-621-2208Maria.cantor@ariad.comorFor Media:Liza Heapes, 617-621-2315Liza.heapes@ariad.com